1. Overview of the HIV-associated tuberculosis epidemic -- 2 . Epidemiology of Drug-susceptible, Drug-resistant Tuberculosis and HIV in Africa -- 3. Modelling the HIV-associated TB epidemic and the impact of interventions aimed at epidemic control -- 4. Immune responses to Mycobacterium tuberculosis and the impact of HIV infection -- 5. Clinical Manifestations of HIV-associated tuberculosis in adults -- 6. The tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) -- 7. Diagnosis of HIV-associated tuberculosis -- 8. Recent advances in the treatment of latent tuberculosis infection among adults living with HIV -- 9. Treatment of drug-sensitive tuberculosis in persons with HIV -- 10. Drug-resistant TB and HIV -- 11. Co-treatment of tuberculosis and HIV: pharmacologic considerations -- 12. HIV and TB in children -- 13. Neurological TB in HIV.

Globally, HIV-associated tuberculosis is one of the most important causes of infection-related death, accounting for over 300,000 deaths worldwide in 2017. The HIV epidemic has undermined TB control efforts in many countries across the world, as the virus has important modifying effects on the pathogenesis, diagnosis, and treatment of TB. The management of HIV-associated TB is also complicated by rapid clinical progression, immune reconstitution inflammatory syndrome, drug-drug interactions, and shared toxicities. The past two decades have yielded thousands of research publications and review articles on HIV-associated TB. HIV and Tuberculosis: A Formidable Alliance consolidates this massive amount of data into a single resource. With contributions from myriad disciplines, including epidemiology, immunology, public health, and clinical medicine, this book provides well-rounded and thorough coverage that will appeal to researchers and clinicians alike.